Samtidig administration af vardenafil med regimer, som indeholder ritonavir inklusiv Kaletra forventes, at resulterer i en 49- gange stigning i vardenafil AUC.
Co-administration of vardenafil with rtionavir containing regimens including Kaletra is expected to result in 49-fold increase in vardenafil AUC.